Products
Every marketed product, with its clinical facts as data
Coverage
- 570,000+ branded and generic products from regions such as the US, Canada, and Europe, each resolved through its ingredients to one drug record.
- Stored at every level of detail, from the brand down to a single strength, each with its own ID.
- Label facts as structured rows: 21,800+ indications, 171,000+ adverse effects, 9,500+ contraindications, and 2,200+ boxed warnings, linked out to other ontologies.
- 1.39M+ structured drug-drug interactions, each with a severity, an evidence level for the type of source behind it, and management advice.
Where it connects
Product
Celebrex
Drugs
Every product resolved through its ingredient to one drug record
productCelebrex
ingredientCelecoxib
drugbank_idDB00482
strength200 mg
dosage_formCapsule
routeOral
Indications
Approved uses with the kind of use and country
conditionOsteoarthritis (OA)
meddra10031161
kindmanagement_of
off_labelfalse
countryUS
+6 more indications
Adverse effects
Each effect, with any rates the label reports: the drug on its own, or beside placebo, an active comparator, or both
effectDyspepsia
meddra10013946
percent (experimental)8.8
percent (placebo)6.2
evidence_typeclinical_trial
routeOral
+219 more adverse effects
Boxed warnings and contraindications
The risk a label boxes, and the patient or exposure it rules out
boxed warning
kindwarning
conditionGastrointestinal Toxicity
meddra10059024
+1 more boxed warning
contraindication
kindhypersensitivity
valueNSAIDs
regionUS
routeOral
+3 more contraindications
Companies
The company on the label, resolved to its parent company
labellers.nameG.D. Searle LLC Division of Pfizer Inc
companies.namePfizer
Zoom in
| product_concept_drugbank_id | title | level | ingredient | strength | route | dosage_form | brand |
|---|---|---|---|---|---|---|---|
| DBPC0248475 | [Celebrex] | 1 | null | null | null | null | Celebrex |
| DBPC0024468 | Celecoxib | 1 | Celecoxib | null | null | null | null |
| DBPC0024472 | Celecoxib Capsule | 2 | Celecoxib | null | null | Capsule | null |
| DBPC0037111 | Celecoxib 200 mg | 2 | Celecoxib | 200 mg | null | null | null |
| DBPC0248483 | Celecoxib Capsule [Celebrex] | 3 | Celecoxib | null | null | Capsule | Celebrex |
| DBPC0248482 | Celecoxib 400 mg Oral [Celebrex] | 4 | Celecoxib | 400 mg | Oral | null | Celebrex |
+264 more product concepts
| source | kind | condition or hypersensitivity | meddra | region | route |
|---|---|---|---|---|---|
| structured_blackbox_warnings | warning | Gastrointestinal Toxicity | 10059024 | [] | [] |
| structured_blackbox_warnings | warning | Cardiovascular Toxicity | [] | [] | [] |
| structured_contraindications | hypersensitivity | NSAIDs | [] | US | Oral |
| structured_contraindications | hypersensitivity | sulfonamides | [] | US | Oral |
| structured_contraindications | hypersensitivity | Acetylsalicylic acid | [] | US | Oral |
| interacting_drug | drug_drugbank_id | severity | evidence_level | action |
|---|---|---|---|---|
| Methotrexate | DB00563 | major | 1 | increase_serum_concentration |
| Warfarin | DB00682 | moderate | 1 | increase_specific_adverse_effects |
| Digoxin | DB00390 | moderate | 1 | decrease_excretion |
| Furosemide | DB00695 | moderate | 1 | decrease_therapeutic_efficacy |
| Lisinopril | DB00722 | moderate | 1 | increase_specific_adverse_effects |
| 2,4-thiazolidinedione | DB11898 | minor | 2 | increase_therapeutic_efficacy |
+1,894 more interactions
| source_name | presentation | meddra | icd10 | hypersensitivity_type |
|---|---|---|---|---|
| NSAIDs (COX-2 Inhibitors) | Anaphylaxis | 10002198 | [] | Type I |
| NSAIDs (COX-2 Inhibitors) | Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum | [] | [] | Type IV |
| NSAIDs (COX-2 Inhibitors) | Drug-Induced Allergic Hepatitis (DIAH) | 10071198 | [] | Type IV |
| Sulfonamide (Non-antibiotic) | Urticaria | 10046735 | L50 | Type I |
| Sulfonamide (Non-antibiotic) | Angioedema | 10002424 | T78.3 | Type I |
| Sulfonamide (Non-antibiotic) | Allergic Skin Reaction | 10012438 | L20 | Unclassified |
| product | strength | dosage_form | country | code | labeller |
|---|---|---|---|---|---|
| Celebrex | 100 mg | Capsule | US | NDC 54569-4671 | A-S Medication Solutions |
| Celebrex | 200 mg | Capsule | US | NDC 54569-4672 | A-S Medication Solutions |
| Act Celecoxib | 100 mg | Capsule | Canada | DIN 02420155 | Teva Italia S.R.L. |
| Act Celecoxib | 200 mg | Capsule | Canada | DIN 02420163 | Teva Italia S.R.L. |
+940 more products
Also in this data
- US drug labelsFDA-approved manufacturer label text: patient medication guides, prescribing information for health professionals, and supplementary sections such as clinical trials and toxicology.
- Therapeutic categoriesThe FDA’s Established Pharmacologic Class, extended to cover other regions.
- Drug categoriesATC codes, MeSH headings, and chemical taxonomy.
- RxNorm conceptsProduct records mapped to RxCUIs.
- Drug-food interactionsReported the same way as drug-drug interactions, with descriptions and management advice.
- PharmacologyMechanism of action, metabolism, absorption, distribution, and elimination, with half-life, clearance, and LD50 as structured values.
Questions it answers
- How do boxed warnings and contraindications compare across a drug class? Efficacy and safety benchmarking
- Which effects are more common on the drug than on placebo, and by how much? Efficacy and safety benchmarking
- Which marketed products contain an ingredient, and in which countries? Competitive clinical landscape
All figures pulled as of November 2026.